Found 534 hits.
|
489. |
Kröger, M.+, Scheffel, J., Shirshin, E. A., Schleusener, J., Meinke, M. C., Lademann, J., Maurer, M., and Darvin, M. E.: Label-free imaging of M1 and M2 macrophage phenotypes in the human dermis in vivo using two-photon excited FLIM. ELIFE 2022: 11; e72819. IF: 7.70 |
o.489
| 436. | Bonnekoh, H., Frischbutter, S., Roll, S., Maurer, M., and Krause, K.+: Tocilizumab treatment in patients with Schnitzler syndrome: an open-label study. J. Allergy Clin. Immunol. Pract. 2021: 9; 2486-2489. IF: 11.02 |
o.436
|
440. |
Farkas, H., Stobiecki, M., Peter, J., Kinaciyan, T., Maurer, M., Aygören-Pürsün, E., Kiani-Alikhan, S., Wu, A., Reshef, A., Bygum, A., Fain, O., Hagin, D., Huissoon, A., Jeseňák, M., Lindsay, K., Grivcheva Panovska, V., Smith, W., Steiner, U. C., Zubrinich, C., Best, J. M., Cornprobst, M., Dix, D., Dobo, S. M., Iocca, H. A., Murray, S. C., Nagy, E., Nagy, E., and Sheridan, W. P.+: Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin. Transl. Allergy 2021: 11; e12035. IF: 5.66 |
o.440
|
480. |
Altrichter, S., Staubach, P., Pasha, M., Sing, B., Chang, A. T., Bernstein, J. A., Rasmussen, H. S., Siebenhaar, F., and Maurer, M.+: An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J. Allergy Clin. Immunol. 2022: 149; 1683-1690. IF: 14.20 |
o.480
| 169 | Krause, K., Mahamed, Aos, Weller, K., Metz, M., Zuberbier, T., and Maurer, M.+: Efficacy and safety of canakinumab in urticarial vasculitis: an open label study. J. Allergy Clin. Immunol. 2013: 132; 751-754. IF: 11.25 |
| 303 | Hollis, K.+, Proctor, C., McBride, D., Balp, M. M., McLeod, L., Hunter, S., Tian, H., Khalil, S., and Maurer, M.: Comparison of urticaria activity score over 7 days (UAS7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. Am. J. Clin. Dermatol. 2018: 19; 267-274. IF: 3.84 |
| 238 | Weller, K., Krüger, R., Maurer, M.+ and Magerl, M.: Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angioedema. Clin. Exp. Dermatol. 2016: 41; 91-93. IF: 1.58 |
| 210 | Schoepke, N., Młynek, A., Weller, K., Church, M. K.+, and Maurer, M.: Symptomatic dermographism: an inadequately described disease. J. Eur. Acad. Dermatol. Venereol. 2015: 29; 708-712. IF: 2.82 |
| 63 | Vieira dos Santos, R., Młynek, A., Lima, H. C., Martus, P., and Maurer, M.+: Beyond flat weals: validation of a three-dimensional imaging technology that will improve skin allergy research. Clin. Exp. Dermatol. 2008: 33; 772-775. IF: 1.78 |
| 84 | Konstantinou, G. N., Asero, R., Maurer, M. Sabroe, R. A., Schmid-Grendelmeier, P., and Grattan, C. E. H.+: EAACI/GA²LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009: 64; 1256-1268. IF: 6.38 |
o.084